Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the LOCOMMOTION trial (NCT04035226) – the first prospective study of the efficacy and safety of real-life standard of care (SOC) regimens in patients with relapsed/refractory (R/R) multiple myeloma – and shares an update on interim analysis findings. Interim results demonstrated that heavily pretreated, triple-class exposed patients with R/R multiple myeloma continue to progress after multiple lines of therapy and have poor outcomes. Dr Mateos highlights the lack of SOC for triple-class refractory patients and concludes that new treatments with novel mechanisms of action are needed. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.